Providers urge FTC to probe PBM practices

Providers want the Federal Trade Commission to investigate pharmacy benefit managers’ business practices, but PBMs and insurers say pharmaceutical manufacturers are to blame for sky-high drug prices.

The FTC published a notice in February asking for input on how PBM practices including rebates and fees, potentially anticompetitive contractsm, and attempts to steer patients towards certain pharmacies affect patients and payers. The commission…